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This work describes analyses of the function of the murid herpesvirus 4 strain 68 (MHV-68) M2 gene. A
frameshift mutation was made in the M2 open reading frame that caused premature termination of translation
of M2 after amino acid residue 90. The M2 mutant showed no defect in productive replication in vitro or in
lungs after infection of mice. Likewise, the characteristic transient increase in spleen cell number, V4
T-cell-receptor-positive CD8 T-cell mononucleosis, and establishment of latency were unaffected. However,
the M2 mutant virus was defective in its ability to cause the transient sharp rise in latently infected cells
normally seen in the spleen after infection of mice. We also demonstrate that expression of M2 is restricted to
B cells in the spleen and that M2 encodes a 30-kDa protein localizing predominantly in the cytoplasm and
plasma membrane of B cells.
Murid herpesvirus 4 is an endogenous pathogen of free-
living rodents of the Apodemus genus, e.g., wood mice (2).
Infection of laboratory mice by murid herpesvirus 4 strain 68
(MHV-68; also called HV-68) is an amenable model system
for the study of gammaherpesvirus pathogenesis and for the
development of therapeutic strategies against these viruses (1,
8, 21, 23, 37). Following intranasal inoculation of mice with
MHV-68, a productive infection occurs in the lung (26). This is
cleared around day 10 postinfection (p.i.) by CD8 T cells (9),
though the virus persists in a latent form in epithelial cells at
this site (25). MHV-68 spreads to the spleen, where it also
becomes latent, predominantly within B lymphocytes, but also
in macrophages and dendritic cells (10, 27, 32, 39).
Establishment of latency in the spleen is associated with a
marked splenomegaly, increase in lymphocytes in the spleen
(splenic lymphocytosis) (29), and a subsequent peripheral
mononucleosis that resembles that caused by primary infection
of humans by Epstein-Barr virus (EBV) (28). Splenic lympho-
cytosis, which peaks at day 14 p.i., is driven by CD4 T cells (9,
29) and is dependent on MHV-68-infected B cells in the spleen
(32, 38). Concomitant with the lymphocytosis is a sharp rise in
the number of latently infected B cells, the resolution of which
to a relatively constant baseline level is achieved by CD8 T
cells (9, 38). CD8 T cells along with antibody (17, 25) are
important in the long-term control of persistent infection (6,
25, 38). Mononucleosis peaks at around day 35 p.i. and is
characterized by the massive expansion of a diverse CD8
T-cell population expressing the V4 T-cell receptor (TCR)
chain in conjunction with a variety of TCR  chains (13, 28).
This differs from both EBV-associated mononucleosis and
classical superantigen reactions in that the majority of T cells
are not largely virus specific, nor is their expansion major
histocompatibility complex (MHC) dependent (7, 8). How-
ever, the V4 T-cell expansion is dependent upon the pres-
ence of MHV-68-infected B cells and CD40 ligand-dependent
CD4 T-cell help (5, 12).
The left end of the unique region of the MHV-68 genome
has attracted considerable interest due to the presence of four
open reading frames (ORFs) (M1, M2, M3, and M4) and eight
viral tRNA-like genes (vtRNAs), none of which have a homo-
logue in other gammaherpesvirus genomes (3, 21, 35). M2 has
attracted particular interest because its expression is restricted
to latent infection in vitro and in vivo (15, 36), where the peak
of expression occurs around day 14 p.i. in the spleen (i.e.,
during splenomegaly), consistent with a role in the establish-
ment of latency (30). The 193-amino-acid M2 protein, further-
more, contains an actively recognized CD8 T-cell epitope,
suggesting that immune regulation of M2-expressing cells is
critical for the resolution of splenomegaly and maintenance of
the host-virus equilibrium that underlies viral persistence (15,
30).
Construction of murine gammaherpesvirus with a mutation
in M2. All molecular, cellular, biological, and virological tech-
niques were performed exactly as described in detail by Mac-
rae et al. (20) unless otherwise specified. To assess the function
of M2, we generated a recombinant virus with a 4-bp deletion
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in the M2 ORF. To generate the recombinant, we used a
modification of a technique that we had developed for rescue
of wild-type (MHV-68) virus from the defective MHV-76
strain (20). Here, the 9.5-kbp deletion at the left end of the
unique region of the MHV-76 genome (relative to MHV-68)
was repaired by homologous recombination with a cosmid
(cA8) that contains the relevant region from the wild-type
MHV-68 genome (nucleotide sequence 115165 to 26842). To
construct such a recombinant MHV-68 (rescuant) with a lesion
in the M2 gene, we utilized a SalI restriction site at genome
coordinate 4337 that is unique within cA8 to generate a 4-bp
deletion within the M2 ORF (Fig. 1A). This deletion caused a
frameshift that would result in premature termination of trans-
lation after amino acid residue 90 and mutated the known
cytotoxic T-cell epitope in M2 (Fig. 1B) (15). Specifically, fol-
lowing restriction with SalI (Invitrogen), cA8 was digested with
mung bean nuclease (Invitrogen) to remove the 5 overhang
and then religated to generate cA8M2. To ensure that the
predicted frameshift mutation had been introduced, cosmids
that lacked a HincII restriction site within the targeted SalI site
were identified and subjected to DNA sequence analysis.
To generate recombinant virus, BHK-21 cells were cotrans-
fected with cA8M2 targeting vector and MHV-76 DNA as
described previously (20), and the resulting plaques containing
MHV with the reinserted 9.5-kbp DNA fragment containing
the M2 mutation [76(RM2)] were identified by PCR with
primers that amplified M2 (20). A wild-type rescuant [76(WTR)]
containing the intact M2 gene was similarly generated with cA8
instead of cA8M2. After five rounds of plaque purification by
limiting dilution, recombinant virus was characterized by
Southern blot hybridization and PCR analysis to ensure that it
was free of contaminating MHV-76. The presence and integ-
rity of the M2 and mutated M2 ORF were first tested by
restriction digestion of infected-cell DNA with HincII followed
by Southern blot hybridization with the M2 ORF as a probe.
The results (Fig. 1C) showed the presence of the expected
2.2-kbp and 354-bp HincII fragments in the wild-type rescuant
76(WTR) (the expected 58-bp fragment was too small to be
visualized on the blot). In 76(RM2) DNA the expected 2.2-
kbp fragment was present, and the 354-bp fragment had been
replaced by the predicted fragment of 412 bp due to the dele-
tion of the HincII site at position 4337 and amalgamation of
the 354- and 58-bp fragments. The integrity of the rest of the
leftmost unique portion of the genome was confirmed by
Southern analysis of HindIII-digested DNA with cA8 as a
probe and by PCR analysis for M1 to M4 ORFs as described by
Macrae et al. (20). Further, the gross integrity of the genomes
of the two rescuant viruses was confirmed by restriction anal-
ysis of viral DNA with BamHI, HindIII, and EcoRI (data not
shown). Finally, the integrity of the 4-bp mutation in 76(RM2)
was confirmed by sequencing the DNA obtained by PCR am-
plification of the M2 ORF.
M2 is not required for virus replication in vitro. To assess
potential effects of the mutation in M2 on MHV-68 replication,
we performed single-step virus growth curves (multiplicity of
infection [MOI] of 5) and multistep growth curves (MOI of
0.01) for MHV-76, 76(WTR), and 76(RM2) in BHK-21 cells.
As shown in Fig. 2A and B, all three viruses replicated with
similar efficiency and in a similar fashion as that reported
previously for MHV-68 (20). This result was not totally unex-
pected, since M2 is not expressed to any great extent during
productive MHV-68 infection (15, 36), and MHV-76 replicates
normally in tissue culture (20). Recent experiments by Jacoby
et al. (16), furthermore, have yielded similar results with re-
spect to lack of a contribution by M2 to virus replication.
Effect of M2 on productive replication in the lung. The
influence of M2 on productive infection in vivo was assessed by
infecting groups of BALB/c mice with MHV-76, 76(WTR),
and 76(RM2) and monitoring infectious virus in the lungs at
various times p.i. by plaque assay. The data in Fig. 2C demon-
strated that there was no significant quantitative difference
between the maximal titers achieved by infectious wild-type
rescuant 76(WTR) (the equivalent of MHV-68) and those
achieved by MHV-76; however, MHV-76 was cleared slightly
more quickly. By contrast, the yield of 76(RM2) was mini-
mally but significantly higher than that of either MHV-76 or
76(WTR) (day 5, P  0.001), and infectious virus remained
detectable through day 10 p.i. The results obtained for
MHV-76 and 76(WTR) are similar to those reported previ-
ously (20). Unexpectedly, the mutation in M2 appeared to
slightly enhance virus production in vivo. The reason for this is
not clear, and, although the difference was statistically signifi-
cant, it is unlikely that this relative increase in titer by only 1 log
over 76(WTR) in the context of a 4.5-log titer is of biological
significance, particularly given that the rate of clearance of
76(RM2) from the lungs was similar to that of 76(WTR).
Recent experiments by Jacoby et al. (16) also showed the lack
of a contribution of M2 to virus replication. Thus, M2 does not
negatively influence virus replication upon primary infection.
Splenic lymphocytosis is not affected by mutation of M2.
The total number of splenic lymphocytes was determined in
mice at various time points after infection with MHV-76,
76(WTR), and 76(RM2). As illustrated in Fig. 2D, 76(WTR)
induced a characteristic transient increase in splenic lympho-
cyte number that peaked at day 14 p.i. MHV-76 infection also
caused an increase in cellularity, but cell numbers were signif-
icantly lower than those detected after 76(WTR) infection
(day 14, P  0.001; day 21, P  0.01). In contrast, 76(RM2)
induced a transient increase in spleen cell number of similar
intensity and duration as that induced by 76(WTR). Thus, the
mutation in M2, unlike the deletion present in MHV-76, did
not affect the ability of MHV-68 to cause splenic lympho-
cytosis.
It was possible, however, that even though the mutation in
M2 did not influence the overall number of cells in the spleen,
specific cell subpopulations could have been affected. There-
fore, we determined the relative numbers of CD19 B cells
and CD8 and CD4 T cells within spleens at day 14 p.i. by
fluorescence-activated cell sorting (FACS) analysis. The re-
sults (Fig. 3) indicated that similar relative levels of CD19
and CD8 cell populations were observed in mice infected
with 76(WTR), 76(RM2), and MHV-76. However, while
there was a similar level of CD4 cells in mice infected with
76(WTR) and 76(RM2), the number of this subset was sig-
nificantly elevated by comparison in MHV-76-infected animals
(P  0.007 by t test). In a similar fashion, the activation status
of CD8 and CD4 T cells was determined by coanalysis of
the levels of CD62 ligand (CD62L) expression, as cells express-
ing low levels of CD62L (CD62Llow) are more activated. As
illustrated in Fig. 3, there was no difference in the numbers of
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activated CD8 T cells in mice infected with any of the three
viruses. However, there was a significantly increased number of
activated CD4 cells in MHV-76-infected mice compared to
those infected with 76(WTR) and 76(RM2) (P  0.007 by t
test). The relative increase in CD4 CD62Llow cells in MHV-
76-infected mice was similar to the relative increase in CD4
cells, indicating that there was no difference in the proportion
of activated CD4 cells in these mice. Thus, mutation in M2
did not affect the relative proportions or activation of the
major spleen cell subsets that contribute to MHV-68-induced
lymphocytosis.
Disruption of M2 affects the normal pattern of latency.
Latent virus in the spleen was first measured at various times
p.i. by an infective center (IC) assay (Fig. 2E). In mice infected
with 76(WTR), measurable latent (i.e., reactivated) virus could
be detected at day 7 p.i. and peaked at day 14 p.i.; by day 31 p.i.
a level of approximately 400 ICs per spleen had been estab-
lished. By contrast, in mice infected with MHV-76, the day 14
spike in the number of latently infected cells characteristic of
wild-type MHV-68/76(WTR) was not observed, and overall
the amount of latently infected cells detected was significantly
less (day 14, P  0.001). MHV-76 ICs were still detectable at
day 31 p.i., at levels of approximately 50 per spleen, i.e., one-
eighth of that obtained with wild-type MHV-68 infection. ICs
in 76(RM2)-infected mice were detectable at day 7 p.i., and
by day 14 latency had been established at a relatively constant
level of approximately 5,000 ICs per spleen through day 31 p.i.
At day 14 p.i. this was a significantly lower level than that
observed in 76(WTR)-infected mice (P  0.001) and signifi-
cantly higher than that in MHV-76 infection (P  0.001). The
number of latently infected cells did not decrease from day 14
through 21 p.i. and was 1 log higher than that in 76(WTR)
infection at day 31 p.i. (P  0.01). These results indicated that
mutation of M2 severely affected the characteristic acute rise in
ICs (latently infected cells) within the spleen during primary
infection and ultimately resulted in an increased level of la-
tently infected cells. It should be noted that we did not detect
preformed infectious virus in the spleen at any of the time
points analyzed, which would have indicated a significant pres-
ence of productively infected cells. Thus, we conclude that the
results obtained with the IC assay represented reactivation
from latent infection.
Because the mutation in M2 could be negatively affecting the
ability of the virus to reactivate from latency, also resulting in
lower estimates of latently infected cells, we determined the
viral genome copy number in the spleens of infected mice by
quantitative fluorescent PCR (QF-PCR). We have previously
shown that genome copy number correlates directly with the
number of latently infected cells in MHV-68-infected mice as
determined by a limiting dilution reactivation assay (33). DNA
was therefore isolated from the spleens of mice at days 14
(peak of lymphocytosis) and 46 p.i. and subjected to QF-PCR.
The results (Fig. 2F) indicated that, at day 14 p.i. with all three
viruses, viral DNA copy number was in good agreement with
the IC assay, i.e., DNA copy number and ICs obtained from
mice infected with MHV-76 and 76(RM2) were approximately
10-fold lower than in 76(WTR)-infected mice (compare Fig. 2E
and F). A positive correlation between copy number and ICs
was also observed at day 46 p.i. However, the number of viral
genomes was 50-fold higher in 76(RM2)-infected mice than
in 76(WTR)-infected mice, a difference that was statistically
significant (P  0.0001) as determined by the Student t test. By
FIG. 1. Targeted mutation of the M2 gene in MHV. (A) Schematic
representation of the left end of the MHV-68 genome. ORFs are
shown as shaded arrows, and the eight vtRNAs are shown as small
arrowheads. TRs, terminal repeat elements. Note that the M2 ORF is
within the second exon of the M2 mRNA. The positions of the HincII
restriction sites (genomic coordinates given) used to evaluate recom-
binant virus DNA are shown above. The position of the M2 probe used
in Southern analysis of viral DNA is shown below. (B) Sequence of the
M2 gene and protein surrounding the site of the introduced 4-bp
deletion (shaded box) at the unique SalI restriction site. The amino
acid sequence of the known cytotoxic T-lymphocyte epitope within M2
is shown in underlined italic boldface. (C) Southern blot analysis of
DNA isolated from BHK-21 cells infected with MHV-76, 76(WTR), or
76(RM2) and digested with HincII. The blot was hybridized to a
32P-labeled M2 DNA probe (nucleotides 4000 to 4606). The positions
of molecular size markers (in base pairs) within the gel are shown to
the left of the autoradiograph.
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FIG. 2. Biological characterization of viruses. In each panel data obtained from infection with MHV-76 (E), 76(RM2) (), and 76(WTR) ()
are shown. All infections of mice (BALB/c) were intranasal with 2 	 105 PFU of virus. (A) Single-step growth curve comparing virus replication
in BHK-21 cells infected at an MOI of 5. Data are representative of two independent experiments, each done in duplicate. (B) Multistep growth
curve comparing replication of viruses in BHK-21 cells at an MOI of 0.01. Data are representative of two independent experiments, each done
in duplicate. (C) Virus replication in the lung; data shown are the mean virus titers obtained from four mice per group at each time point. (D) Total
spleen cell number within infected mice; shown are the mean cell numbers obtained from four infected mice per group at each time point.
(E) Latently infected cells in the spleens of infected mice as determined by IC assay; data from four mice per group are shown at each time point.
No preformed infectious virus was detected in this assay (data not shown). (F) Quantification of viral DNA in the spleen. Shown are the viral
genome copy numbers per 300 ng of DNA as determined by QF-PCR at the indicated days p.i. The results are the mean values obtained from four
mice per time point. In all panels, where indicated, bars represent standard errors of the means and asterisks over points represent a statistically
significant difference from the wild-type value.
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contrast, in our IC assay, the number of latently infected cells
in the spleens of 76(RM2)-infected mice was only 10-fold
higher than that in the 76(WTR)-infected mice. This suggests
that the actual level of latency established by the M2 mutant
virus is higher than reactivable latency, indicating a possible
defect in the ability of the mutant virus to reactivate from
latency.
To confirm that the effects on latency were due to the lesion
in M2, we generated a second recombinant virus with a 256-bp
deletion within the ORF (coordinates 4239 to 4494). This virus
had a similar phenotype in vivo as 76(RM2) (data not
shown). Thus, the effects seen were due to the mutation of M2
and not other secondary mutations in the viral genome. Fi-
nally, to confirm that the observed properties of the 76(RM2)
virus were attributable to the frameshift mutation within the
M2 gene, we determined the sequence of the M2 ORF ampli-
fied from DNA extracted from three separate viral plaques
resulting from reactivation from three different mice at day
14 p.i. with 76(RM2). The results indicated that, in all cases,
the only mutation in the M2 ORF was the 4-bp deletion that we
had originally introduced (data not shown). Thus, we found no
evidence for the selection of M2 revertant or pseudorevertant
viruses in vivo and concluded that the striking reduction in the
number of latently infected cells observed at day 14 p.i. in mice
infected with 76(RM2) was indeed a consequence of the
mutation within M2.
A decrease in the peak of cells latently infected with M2
mutant viruses was also observed by Jacoby et al. (16). This fits
well with previous observations that M2 is expressed during
latency (15, 36) and that the peak of M2 expression in the
spleen appears to occur around day 14 p.i (30). There was,
however, a significantly greater number of latently infected
cells present in the spleens of mice infected with the M2 mu-
tant virus than in spleens of mice infected with MHV-76 at day
14 p.i. Because MHV-76 lacks M1 to M4 and the vtRNAs, one
or more of these genes in addition to M2 likely contributes to
the transient spike or rise in latently infected cells character-
istically observed at this point following primary infection. At
least part of this is due to the M3 protein, a soluble chemokine
binding protein (22, 34), since viruses with M3 deleted have a
defect in their ability to cause this transient rise in latently
infected splenic lymphocytes (4).
A transient rise in latently infected cells shortly after infec-
tion is seen with other gammaherpesviruses such as EBV. The
biological function of this is not known, but it is generally
believed to promote viral persistence by ensuring that a critical
pool of latently infected cells is established prior to maturation
of the host antiviral immunosurveillance. Our results suggest
that this may not be the case, at least for MHV-68, since both
76(RM2) and MHV-76 are capable of establishing long-term
latency. However, it is possible that the transient rise in latently
infected cells may play a more critical role, such as that pro-
posed in EBV infection, in the context of a naturally acquired
MHV-68 infection as opposed to one that is laboratory ac-
quired.
Surprisingly, despite the dramatic reduction in the number
of latently infected spleen cells as a consequence of M2 mu-
tation, the splenic lymphocytosis that is concomitant with the
peak splenomegaly at day 14 p.i. was not significantly affected.
Thus, for the first time we have been able to separate the spike
in latently infected cells from the concurrent lymphocytosis, in
which all spleen lymphocyte subsets are expanded (29). By
contrast, MHV-76 was severely disabled in its ability to induce
lymphocytosis, strongly suggesting that one or more of the
genes M1, M3, and M4 or the vtRNAs are primarily responsi-
ble for this phenomenon. The precise causes of the transient
lymphocytosis and rise in latently infected cells are unclear, but
it has been assumed that they are interdependent. Specifically,
in addition to their temporal overlap during primary infection,
both are dependent upon latently infected B cells (32) and
CD4 T cells (29). This led to two alternative hypotheses (24).
The first is that the virus drives the expansion of latently in-
fected B cells and that CD4 and CD8 T-cell expansion is in
reaction to this. The second is that virus infection causes acti-
vation and expansion of CD4 T cells, which in turn drive the
expansion of latently infected B cells and CD8 T cells. In the
light of our present results, however, it seems likely that an
alternative mechanism is operating, namely, that first the tran-
sient expansion of latently infected cells and splenic lympho-
cytosis are not dependent upon one another; second, transient
expansion of the number of latently infected cells is virus
driven, with M2 playing a major role; and third, the expansion
of noninfected B cells, and CD4 and CD8 T cells, appears
to be in response to latently infected cells, but this is dependent
upon neither high levels of these cells nor M2 expression.
Finally, as indicated above, other viral genes not present in
MHV-76 are key to the expansion of spleen lymphocyte num-
ber.
Given that M2 was required for the expansion of latently
infected cells within the spleen during acute infection, it was
somewhat surprising that mutation of M2 did not negatively
affect the establishment of long-term latency. This is supported
by similar observations obtained with other M2 mutants and
with MHV-76 (16, 20). Interestingly, the level of both reacti-
vable latency and latent genomes maintained long-term by our
M2 mutant in the spleen was significantly higher than that for
FIG. 3. FACS analysis of spleen cell subsets. Spleen cells from
infected mice (as indicated) were stained with monoclonal antibodies
to the indicated cell surface markers and analyzed by FACS. In each
case the percentage of positive cells was calculated, and the means with
standard errors of four individual animals are shown. Asterisks repre-
sent a statistically significant difference from the wild-type value.
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either wild-type virus or MHV-76 (Fig. 2E and F). An eleva-
tion of the level of genome-positive cells in the spleen after
peritoneal infection was also observed by Jacoby et al. (16),
using a similar mutation in M2 (introduction of a stop codon).
It is possible, therefore, in a way analogous to EBV LMP-2A,
that M2 functions in part by inhibiting or preventing the over-
expansion of virus-infected cells within the host. Since this
expansion is not observed in mice infected with MHV-76, this
effect is most likely dependent upon other gene products
present at the left end of the MHV-68 genome.
M2 does not affect V4-positive mononucleosis. To assess
whether the MHV-68-induced mononucleosis is in response to
the M2 gene product, C57BL/6 mice were infected with MHV-
76, 76(WTR), and 76(RM2), and their peripheral blood was
assayed by FACS at day 35 p.i. as described previously (12).
Two parameters of mononucleosis were measured: the pres-
ence of activated CD8 lymphocytes (CD62Llow) and the lev-
els of V4 CD8 T cells. As shown by the representative data
presented in Fig. 4, the pattern of CD62L staining was similar
regardless of the strain of infecting virus. Specifically, in each
case the majority (99%) of CD8 T cells expressed low levels
of CD62L. By contrast, mice infected with either 76(WTR) or
76(RM2) had elevated levels of V4 CD8 cells (24 and
22%, respectively) relative to mice infected with MHV-76,
which as expected had relatively normal levels (4%) of V4
CD8 T cells. Thus, the mutation in M2 affected neither the
presence of elevated levels of activated CD8 T cells in the
periphery nor the high level of V4 CD8 cells in this pop-
ulation. Thus, MHV-68-induced mononucleosis is dependent
on a gene other than M2 that is present within the leftmost 9.5
kbp of the unique portion of the MHV-68 genome, i.e., that
deleted in MHV-76.
Like lymphocytosis in the spleen, the viral factors responsi-
ble for the generation of either the peripheral CD8 T-cell
mononucleosis or the abnormal expansion of V4 TCR cells
within this population have not been identified. However, like
the transient expansion of spleen cells, V4 TCR CD8
expansion is dependent upon the presence of MHV-68-in-
fected B cells and CD40 ligand-dependent CD4 T-cell help
(5, 12). The mutation in M2 affected neither mononucleosis
nor expansion of V4 T cells (Fig. 4). However, while
MHV-76 induced peripheral mononucleosis, it did not pro-
mote expansion of V4 T cells. This indicates that specific
viral products are required for V4 T-cell expansion and that
they reside within the deletion present in MHV-76, excluding
M2.
M2 expression occurs within B cells in the spleen. Our
previous analyses have shown that M2 mRNA is actively ex-
FIG. 4. FACS analysis of peripheral blood lymphocytes. Peripheral blood cells of mice infected for 35 days with the indicated viruses were
stained with labeled with monoclonal antibodies either to CD8 and V4 or to CD8 and CD62L and subjected to FACS. Data are representative
of at least three separate experiments.
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pressed at day 14 p.i. in the spleens of mice infected with
MHV-68 and is detectable sporadically in splenic B cells at
later time points p.i. (11, 15, 30). In addition to B cells,
MHV-68 also infects splenic macrophages and dendritic cells
(10, 39). To ascertain in which spleen cell type(s) M2 is ex-
pressed, C57BL/6 mice were infected intranasally with MHV-
68. B cells (total, activated, and resting), macrophages, and
dendritic cells were then isolated by FACS from the spleens at
day 14 p.i., and total RNA extracted from these cells was
subjected to nested reverse transcription-PCR (RT-PCR) as
described previously (11). In addition to M2, the expression of
the MHV-68 M3 and cellular -actin mRNAs were analyzed
using primers shown in Table 1. M3 was chosen because it is
also characteristically expressed in the spleen at this time point
(30, 36); detection of the -actin mRNA served as an indicator
of mRNA integrity and a positive control for amplification. In
serial dilution assays, our RT-PCR assay was able to detect M2
mRNA in as few as one S11 cell in 105 MHV-68-negative cells
(BJAB B-lymphoma cells; data not shown). S11 is a latently
infected murine B-cell tumor line (31) that expresses M2
mRNA in virtually all cells (15), and thus the level of M2
expression in these cells is likely to be an accurate represen-
tation of its expression in latently infected cells in vivo. Addi-
tionally, upon spiking cDNA synthesized from the total RNA
of MHV-68-negative cells with a full-length M2 cDNA, we
determined that the sensitivity of our PCR assay was sufficient
to detect between one and five copies of the M2 target (data
not shown).
To detect gene expression in spleen cell subsets, RNA from
a total of at least three independent sorts for each cell type was
analyzed. As shown in Table 2, whereas M3 transcripts were
detected in all cell subsets analyzed, M2 mRNA was detected
only in B cells, both activated and resting. -Actin mRNA was
equivalently amplified in all RNA samples analyzed (data not
shown). Our other studies (11) have shown that the frequency
of infection within each cell subset (determined by limiting
dilution analysis-PCR), though highest in activated B cells, is
well within the level of detection of this assay (10
5), as de-
scribed above. Thus, these data strongly suggest that M2 ex-
pression in the spleen is B cell specific.
Previous analyses of M2 have shown that it is expressed
within the latently infected S11 B-cell line in vitro (15) and
during latency in vivo, most abundantly (as determined by
RT-PCR) during the peak of lymphocytosis in the spleen at
day 14 p.i (30, 36). Here, we extend these analyses by showing
that M2 is expressed predominantly, if not solely, within B cells
and not in splenic macrophages and dendritic cells that also
harbor latent virus. A previous report of M2 expression in
spleen and peritoneal exudate cells following intraperitoneal
inoculation of MT knockout mice (36), which fail to develop
mature B cells due to an inability to express the immunoglob-
ulin M heavy chain (m), would seem to be inconsistent with
our finding here of B-cell-restricted expression of M2. How-
ever, recent findings indicate that MT mice do indeed gen-
erate B cells, through an m-independent pathway, that spe-
cifically produce immunoglobulin A (19). It is possible,
therefore, that such B cells were the source of M2 expression in
MHV-68-infected MT mice.
The M2 protein is cytoplasmic and plasma membrane as-
sociated in B cells. The predicted amino acid sequence of the
M2 protein lacks sufficient homology to any known protein or
functional motif that would suggest its role during MHV-68
infection. Therefore, as a first step in defining M2 function, we
transiently expressed it within mouse A20 B cells (18). Because
of the lack of an adequate M2-specific antibody, M2 was ex-
pressed as either an N- or C-terminal fusion with enhanced
green fluorescent protein (EGFP) by using the vectors
pEGFP-C1 and pEGFP-N1 (Clontech) to aid in its detection.
TABLE 1. RT-PCR primers used in this study
Gene Round Sequence MHV-68 genomic coordinatesa Product size (bp)
M2b 1st CTTCCTTAGCCAGTCTCTTC 5872–5853 650
ACCTTCACTGTTACTCCTCG 4018–4037
2nd TGAAGCGGTGTTACAGACTC 5848–5829 573
GGTGGAATAATAGGAAGACG 4071–4090
M3 1st GTGGCACACCAGTGAATGAC 6916–6897 589
GGTGAAGTGAGAGAATCCAG 6328–6347
2nd CAGAAGAGACTCCAGAGGAG 6859–6840 505
AGGTCAGCTAGGATCAAGTG 6355–6374
-Actin TGTGATGGTGGGAATGGGTCA NAc 514
TTTGATGTCACGCACGATTTC
a Genomic coordinates are according to the work of Virgin et al. (35).
b M2 primer sequences are derived from different exons, and therefore, the product size is shorter than the genomic distance between 5 and 3 primers.
c NA, not applicable.
TABLE 2. MHV-68 M2 and M3 expression in spleen at day 14 p.i.a
Cellsb M2 M3
B cells (total) 3/3 3/3
Resting B cells 3/5 4/5
Activated B cells 4/5 5/5
Ms 0/3 3/3
DCs 0/4 4/4
a Data represent positive RT-PCR results per number of individual sorts
analyzed for each MHV-68 ORF; -actin was equivalently detected in all sam-
ples. M, macrophage; DC, dendritic cell.
b Cells sorted as B220 CD11b
 CD11c
 (total B cells; mean purity, 99.64%),
B220 peanut agglutinin (PNA)low (resting B cells; mean purity, 98.15%), B220
PNAhigh (activated B cells; mean purity, 98.64%), B220
 CD11b CD11c

(Macrophages; mean purity, 96.34%), and B220
 CD11b/
 CD11c (dendritic
cells; mean purity, 92.86%).
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Immunoblot analysis of transfected A20 cells revealed the
presence of a novel protein of 60 kDa in the lysates of those
cells transfected with an expression vector encoding either the
N- or C-terminal EGFP-M2 fusion protein (data not shown).
Accounting for the mass of the EGFPs, the molecular mass of
M2 is 30 kDa. This was in good agreement with the size of a
hemagglutinin-tagged version of M2 stably expressed in A20
cells (data not shown) and previously reported unpublished
observations by others (16). Of particular note was the obser-
vation that the molecular mass of M2 in the fusion was con-
siderably greater than its predicted molecular mass of 22 kDa.
The molecular mass of the protein by in vitro transcription and
translation analysis was 26 kDa (data not shown). Thus, the
molecular mass of 30 kDa for native M2 is most likely due to
a combination of an aberrant migration of the unmodified
polypeptide backbone in sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis and a contribution of approximately 4
kDa by posttranslational modification(s).
To determine the subcellular localization of the M2 protein,
transiently expressed EGFP-M2 was examined in A20 cells at
24 h posttransfection by confocal microscopy with a Leica
TCSNT confocal system. In some experiments, cells were fixed
in 4% (wt/vol) paraformaldehyde and stained with either pro-
pidium iodide (PI; in phosphate-buffered saline containing 10
g of RNase A [Qiagen] and 1 g of PI [Molecular Probes] per
ml for 30 min at 37°C in the dark) to label DNA or tetramethyl
rhodamine isocyanate (TRITC)-labeled reagents to detect spe-
cific cellular markers. Cells were observed using a combination
of laser light wavelength and band filter specific for EGFP (488
and 525/50 nm) or PI-TRITC (568 and 600/30 nm). Image
FIG. 5. Confocal microscopic analysis of M2 expression. A20 cells were transfected with either pEGFP-C1 (A to C) or pEGFP-C1/M2 (D to
I) and after 48 h were either fixed, permeabilized, and then counterstained with PI or stained with TRITC-conjugated antibody to MHC class II
antigens and then fixed. Cells were then visualized using a Leica TCNTS confocal microscope with combinations of laser light wavelength and band
filter specific for EGFP (488 and 525/50 nm [A, D, and G]) or for PI and TRITC (568 and 600/30 nm [B, E, and H]). Image analysis with Leica
software enabled the overlaying of these two images (C, F, and I). All images are shown at the same magnification.
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analysis was then used to form a picture with the resulting two
images overlaid. Representative results are shown in Fig. 5.
Cells transfected with empty vector (pEGFP-C1) displayed a
diffuse pattern of EGFP-specific fluorescence that was present
throughout the cytoplasm and nucleus as evidenced by the
covisualization of EGFP and PI (Fig. 5A to C). In cells trans-
fected with pEGFP-C1/M2 (Fig. 5D to F) the EGFP-M2-spe-
cific fluorescence was primarily localized in patches near the
cell margins and in the nucleus, as well as diffusely at a lower
intensity throughout the nucleus and cytoplasm. However, nu-
clear staining was not universal and there appeared to be little
crossover between the EGFP-M2 and PI fluorescence. A sim-
ilar pattern of staining was seen with the C-terminal fusion
protein encoded by pEGFP-N1/M2 and when a hemagglutinin
epitope-tagged molecule was expressed in the same cells (data
not shown). These results were consistent with M2 being prin-
cipally localized in patches at or near the plasma membrane
and within areas in the nucleus that did not contain chromatin.
Because the cytoplasm in B cells is small and it is thus often
hard to distinguish membrane and cytoplasmic fluorescence,
we immunostained pEGFP-C1/M2-transfected cells with TRITC-
labeled anti-MHC class II (monoclonal antibody SW 73.2 [14])
(Fig. 5G to I). MHC class II glycoprotein molecules are princi-
pally localized to the plasma membrane of B cells. The EGFP-
M2-specific fluorescence was as observed previously, and a pro-
portion of the patches of EGFP-M2 clearly colocalized with
MHC class II, as evidenced by yellow staining when the two
images were overlaid. Similar results were obtained when anti-
CD19 (another B-cell surface marker) was used instead of anti-
MHC class II (data not shown). Additionally, no colocalization
was observed between EGFP-M2 and BODIPY ceramide (a
marker for the Golgi apparatus) or LysoTracker Red DND-99 (a
marker for lysosomes) (data not shown). Thus, the above results
are consistent with a proportion of the M2 protein being cyto-
plasmic and a proportion being localized in patches either at or
extremely close to the plasma membrane.
Putative function of M2. Our M2 expression data suggest
that the effects of mutation of M2 as discussed above are B cell
specific. Thus, in some respects, M2 function may be analogous
to the perceived collective function of the EBV growth pro-
gram of latency gene expression (which includes several B-cell-
restricted genes): principally, to drive the rapid expansion of
infected cells to establish a critical pool of latently infected
cells. The function of M2, however, remains enigmatic. Pre-
liminary biochemical analyses failed to demonstrate any post-
translational modification of the protein that might have shed
light on this problem. While the apparent effects of M2 ex-
pression in the spleen and its localization to the cytoplasm and
plasma membrane may argue for a role in cell signaling, the
precise function of M2 and its specific role in MHV-68 latency
remain to be determined.
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